To view this email as a web page, click here.

 
Welcome to The Weekly Skin Scan, where our editors will keep you up-to-date on the latest news and research that could impact your practice. Browse more stories here.
 
Acne and Rosacea
 
Acne patients open to antibiotic-free treatment
Acne patients are open to using effective antibiotic-free treatments if their prescriber offers them, says a recent study.
 
IL-17 inhibitors for rosacea
New options may be possible for treatment-resistant and severe rosacea with the use of IL-17 inhibitors as researchers conduct studies on effectiveness.
ADVERTISEMENT
 
Psoriasis and Atopic Dermatitis
 
Ustekinumab levels in PsO
Study shows measurement of early ustekinumab levels could be used to direct treatment strategy in psoriasis.
 
Adult vs. pediatric AD
Atopic dermatitis presents differently depending on whether the patient is an adult or child. This means that different treatments may be more effective in an adult than children and vice versa.
ADVERTISEMENT
 
Skin Cancer
 
NMSC increases in the elderly
As age is the strongest risk factor in NMSC, dermatologists can see an increase in this type of cancer in elderly patients, and treatment preferences vary.
 
Connect with us on Twitter and Facebook for daily updates.
 
From our Latest Issue
 
Dermatology Times cover
Ortho Dermatologics Aspire Higher scholarship recipient shares story, dreams
 
Prior Authorizations process compromises ability to treat patients satisfactorily
 
Am I liable if the patient wasn’t mine?
 
ADVERTISEMENT
Celebrate Greatness – Recognize an Innovator
Giants of DermatologyTM is a peer-to-peer nomination program that salutes excellence within the dermatology community and honors physicians and industry leaders whose efforts continue to inspire, inform, and advance treatment. Know an individual who deserves to be celebrated? Nominate them today!
 
JOB OPPORTUNITIES
 
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.